The drugmaker narrowed its losses by 90% to -$70.2 million, or -20¢ per share, on sales growth of 7.1% to $3.86 billion for the 3 months ended Dec. 31, compared with Q4 2015. Adjusted to exclude 1-time items, earnings per share were $3.90, a full 14¢ ahead of The Street, where analysts were looking for sales of $3.77 billion.
Get the full story at our sister site, Drug Delivery Business News.
The post Allergan ticks up on Q4, 2016 beats appeared first on MassDevice.
from MassDevice http://ift.tt/2kSH3RV
Cap comentari:
Publica un comentari a l'entrada